These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6469936)

  • 1. Naltrexone treatment for addicted health-care professionals: a collaborative private practice experience.
    Ling W; Wesson DR
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):46-8. PubMed ID: 6469936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naltrexone in addicted business executives and physicians.
    Washton AM; Pottash AC; Gold MS
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):39-41. PubMed ID: 6088468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naltrexone treatment in a jail work-release program.
    Brahen LS; Henderson RK; Capone T; Kordal N
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):49-52. PubMed ID: 6469937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the National Institute on Drug Abuse in the development of naltrexone.
    Ginzburg HM; Glass WJ
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):4-6. PubMed ID: 6088469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with naltrexone in suburban opioid addicts.
    Tennant FS; Rawson RA; Cohen AJ; Mann A
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):42-5. PubMed ID: 6469935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naltrexone: a clinical perspective.
    Greenstein RA; Arndt IC; McLellan AT; O'Brien CP; Evans B
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):25-8. PubMed ID: 6469933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.
    Mintzer IL; Eisenberg M; Terra M; MacVane C; Himmelstein DU; Woolhandler S
    Ann Fam Med; 2007; 5(2):146-50. PubMed ID: 17389539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naltrexone in addicted physicians and business executives.
    Washton AM; Gold MS; Pottash AC
    NIDA Res Monogr; 1984; 55():185-90. PubMed ID: 6443377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ultra-rapid detoxification of opiate dependent patients: review of the literature, critiques and proposition for an experimental protocol].
    Fontaine E; Godfroid IO; Guillaume R
    Encephale; 2001; 27(2):187-93. PubMed ID: 11407272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Naltrexone and prevention of opiate dependence relapse. An Italian experience].
    Cibin M; Gentile N; Ferri M; Gallimberti L
    Minerva Psichiatr; 1989; 30(2):93-8. PubMed ID: 2779401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naltrexone induction: psychologic and pharmacologic strategies.
    Kleber HD; Kosten TR
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):29-38. PubMed ID: 6469934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of favorable outcome following naltrexone treatment.
    Greenstein RA; Evans BD; McLellan AT; O'Brien CP
    NIDA Res Monogr; 1983 Apr; 43():294-301. PubMed ID: 6410264
    [No Abstract]   [Full Text] [Related]  

  • 13. Naltrexone plus benzodiazepine aids abstinence in opioid-dependent patients.
    Stella L; D'Ambra C; Mazzeo F; Capuano A; Del Franco F; Avolio A; Ambrosino F
    Life Sci; 2005 Oct; 77(21):2717-22. PubMed ID: 15979652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update of naltrexone treatment.
    O'Brien CP; Greenstein R; Woody GE
    NIDA Res Monogr; 1978; (19):315-20. PubMed ID: 218107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychotherapy and naltrexone in opioid dependence.
    Resnick RB; Washton AM; Stone-Washton N
    NIDA Res Monogr; 1981 Feb; 34():109-15. PubMed ID: 6783917
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence.
    Mannelli P; Patkar AA; Peindl K; Murray HW; Wu LT; Hubbard R
    J Clin Psychopharmacol; 2007 Oct; 27(5):468-74. PubMed ID: 17873678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics.
    Verebey K
    NIDA Res Monogr; 1981; 28():147-58. PubMed ID: 6791001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naltrexone for opioid addiction.
    Med Lett Drugs Ther; 1985 Feb; 27(680):11-2. PubMed ID: 3969057
    [No Abstract]   [Full Text] [Related]  

  • 19. Unintentional rapid opioid detoxification: case report.
    Singh SM; Sharma B
    Psychiatr Danub; 2009 Mar; 21(1):65-7. PubMed ID: 19270623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine.
    Reece AS
    J Subst Abuse Treat; 2009 Oct; 37(3):256-65. PubMed ID: 19394789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.